ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2019 Pre-Market Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY 2019
Pre-Market earnings guidance on Tuesday morning. The company provided earnings per share guidance of 5.06-5.23 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.14. The company issued revenue guidance of $209-212 million, compared to the consensus revenue estimate of $209.67 million.

Shares of ANIP opened at $60.05 on Tuesday. The firm has a 50-day simple moving average of $67.04 and a two-hundred day simple moving average of $72.11. The stock has a market cap of $744.99 million, a PE ratio of 13.03 and a beta of 1.96. ANI Pharmaceuticals has a 1-year low of $36.92 and a 1-year high of $86.96. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.07 and a quick ratio of 0.80.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Wednesday, November 6th. The specialty pharmaceutical company reported $1.23 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.43 by ($0.20). ANI Pharmaceuticals had a return on equity of 28.28% and a net margin of 7.58%. The company had revenue of $51.30 million for the quarter, compared to analysts’ expectations of $56.10 million. During the same period in the previous year, the business posted $1.29 EPS. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. As a group, sell-side analysts expect that ANI Pharmaceuticals will post 4.58 earnings per share for the current fiscal year.

A number of equities research analysts have recently weighed in on ANIP shares. Zacks Investment Research cut ANI Pharmaceuticals from a hold rating to a strong sell rating in a research note on Tuesday, November 12th. Guggenheim initiated coverage on ANI Pharmaceuticals in a research note on Thursday, September 12th. They set a buy rating and a $76.00 target price on the stock. BidaskClub upgraded ANI Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, October 22nd. Finally, ValuEngine upgraded ANI Pharmaceuticals from a strong sell rating to a sell rating in a report on Tuesday, November 19th. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. ANI Pharmaceuticals has an average rating of Hold and a consensus price target of $86.40.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Read More: Google Finance Portfolio

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply